PASGPassage Bio
About Passage Bio
Passage Bio (NASDAQ:PASG) is a biotechnology firm at the forefront of developing genetic medicines targeting the central nervous system (CNS), with the aim of addressing rare, life-threatening disorders. The company's pipeline includes multiple gene therapy programs in various stages of development, each focusing on specific conditions such as GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. By leveraging cutting-edge technology and innovative research strategies, Passage Bio strives to bring transformative treatments from the lab to patients in need. Their objective is to pioneer breakthrough therapies that can significantly improve the quality of life for individuals suffering from debilitating genetic diseases.
What is PASG known for?
Snapshot
Public US
Ownership
2017
Year founded
58
Employees
Philadelphia, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Philadelphia, US
Produtos e/ou serviços de Passage Bio
- Gene therapy targeting GM1 gangliosidosis, a severe neurological disorder, aimed at delivering functional genes directly into patients' brains.
- Treatment for Krabbe disease via gene therapy, designed to halt disease progression by replacing defective genes.
- A therapeutic candidate for Frontotemporal Dementia, aiming to restore normal gene function in patients' brains.
- Development of a gene editing tool to potentially correct genetic defects in a range of inherited diseases.
- Research into innovative delivery mechanisms for gene therapies, enabling more efficient and targeted treatment.
- Collaborative efforts with academic and research institutions to discover new gene therapy techniques and applications.
equipe executiva do Passage Bio
- Dr. William Chou M.D.President, CEO & Director
- Ms. Kathleen BorthwickSenior VP, CFO, Principal Financial Officer & Principal Accounting Officer
- Dr. Sue Browne Ph.D.Chief Scientific Officer
- Mr. Stuart M. HendersonChief Business Officer
- Mr. Eden FucciSenior Vice President of Technical Operations
- Dr. Karl Whitney Ph.D.Senior Vice President of Global Regulatory Affairs